Edition:
United States

GTX Inc (GTXI.OQ)

GTXI.OQ on NASDAQ Stock Exchange Capital Market

18.89USD
23 May 2018
Change (% chg)

$-0.52 (-2.68%)
Prev Close
$19.41
Open
$19.30
Day's High
$19.68
Day's Low
$18.75
Volume
32,174
Avg. Vol
29,137
52-wk High
$23.36
52-wk Low
$2.77

Latest Key Developments (Source: Significant Developments)

GTX Inc Q4 Loss Per Share $0.43
Monday, 12 Mar 2018 04:05pm EDT 

March 12 (Reuters) - GTX Inc ::GTX PROVIDES CORPORATE UPDATE AND REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.GTX INC - QTRLY LOSS PER SHARE $0.43.  Full Article

GTX Inc Files For Mixed Shelf Offering Of Up To $150 Mln
Friday, 22 Dec 2017 04:40pm EST 

Dec 22 (Reuters) - GTX Inc ::GTX INC FILES FOR MIXED SHELF OFFERING OF UP TO $150 MILLION - SEC FILING.  Full Article

GTX reports qtrly ‍loss per share $0.53​
Tuesday, 14 Nov 2017 04:05pm EST 

Nov 14 (Reuters) - Gtx Inc ::GTX provides corporate update and reports third quarter 2017 financial results.GTX Inc qtrly ‍loss per share $0.53​.  Full Article

GTX Inc files for offering of up to 8.8 million shares of common stock
Friday, 20 Oct 2017 04:50pm EDT 

Oct 20 (Reuters) - GTX Inc ::GTX Inc files for offering of up to 8.8 million shares of common stock by the selling stockholders .  Full Article

Amzak Health Investors Llc reports 6.15 pct passive stake in GTX as of Sept 29
Tuesday, 10 Oct 2017 04:42pm EDT 

Oct 10 (Reuters) - GTX Inc :Amzak Health Investors Llc reports 6.15 percent passive stake in GTX Inc as of September 29 - SEC Filing‍​.  Full Article

GTX qtrly loss per share $0.04
Tuesday, 9 Aug 2016 07:00am EDT 

Gtx Inc : Gtx provides corporate update and reports second quarter 2016 financial results .Qtrly loss per share $0.04.  Full Article

BRIEF-GTx Updates Phase 2 Enobosarm Clinical Trial Results

* GTX UPDATES PHASE 2 ENOBOSARM CLINICAL TRIAL RESULTS IN STRESS URINARY INCONTINENCE AT 2018 AUA ANNUAL MEETING